3(S)-(Pyrimidin-5-yl)-9-(5,6,7,8-tetrahydro[1,8]naphthyridin-2-yl)-nonanoic acid | 227753-43-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 3(S)-(Pyrimidin-5-yl)-9-(5,6,7,8-tetrahydro[1,8]naphthyridin-2-yl)-nonanoic acid
• 英文别名: 3-(Pyrimidin-5-yl)-9-(5,6,7,8-tetrahydro-[1,8]-naphthyridin-2-yl)-nonanoic acid；3-Pyrimidin-5-yl-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid
• CAS: 227753-43-7
• 化学式: C₂₁H₂₈N₄O₂
• 分子量: 368.479
• InChiKey: DMDDFJFCCZFCKL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  27
• 可旋转键数：
  10
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.52
• 拓扑面积：
  88
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• Alpha V integrin receptor antagonists
  申请人：——

  公开号：US20020040030A1

  公开（公告）日：2002-04-04

  The present invention relates to novel compounds formed by metabolic conversion of compounds of the structural formula depicted below (R═H or Me), pharmaceutical compositions containing such compounds, and their use as &agr;v&bgr;3 integrin receptor antagonists. The compounds of the present invention are useful for inhibiting bone resorption, restenosis, angiogenesis, diabetic retinopathy, macular degeneration, inflammatory arthritis, cancer, and metastatic tumor growth. They are particularly useful for inhibiting bone resorption and for the treatment and prevention of osteoporosis. 1

  本发明涉及通过代谢转化形成的新化合物，其结构式如下所示（R═H或Me），包含此类化合物的药物组合物，以及它们作为αvβ3整合素受体拮抗剂的用途。本发明的化合物对抑制骨吸收、再狭窄、血管生成、糖尿病视网膜病变、黄斑变性、炎症性关节炎、癌症和转移性肿瘤生长具有用处。它们特别适用于抑制骨吸收以及治疗和预防骨质疏松症。
• Amine salt of an integrin receptor antagonist
  申请人：——

  公开号：US20030004171A1

  公开（公告）日：2003-01-02

  The tris(hydroxymethyl)aminomethane (“TRIS”) salt of 3-(pyrimidin-5-yl)-9-(5,6,7,8-tetrahydro-[1,8]-naphthyridin-2-yl)-nonanoic acid is a potent antagonist of the integrin &agr;v&bgr;3 receptor and is useful for the prevention and/or treatment of osteoporosis and vascular restenosis, as well as conditions associated with excessive angiogenesis, such as macular degeneration, diabetic retinopathy, atherosclerosis, inflammatory arthritis, cancer, and metastatic tumor growth. The invention also relates to a process for the preparation of the novel salt as well as pharmaceutical compositions containing the salt and methods of using the salt.

  3-(嘧啶-5-基)-9-(5,6,7,8-四氢-[1,8]-萘啶-2-基)-壬酸的三(羟甲基)氨基甲烷（"TRIS"）盐是整合素&agr;v&bgr；3 受体的强效拮抗剂，可用于预防和/或治疗骨质疏松症和血管再狭窄，以及与过度血管生成有关的疾病，如黄斑变性、糖尿病视网膜病变、动脉粥样硬化、炎性关节炎、癌症和转移性肿瘤生长。本发明还涉及新型盐的制备过程以及含有该盐的药物组合物和使用该盐的方法。
• INTEGRIN RECEPTOR ANTAGONISTS
  申请人：Merck & Co., Inc. (a New Jersey corp.)

  公开号：EP1040098B1

  公开（公告）日：2005-04-27
• Compositions Methods for Treating Chronic Kidney Disease
  申请人：COX Jason M.

  公开号：US20180110762A1

  公开（公告）日：2018-04-26

  This invention relates to the treatment of chronic kidney disease, including diabetic nephropathy, focal segmental glomerulosclerosis (FSGS), nephrotic syndrome, non-diabetic chronic kidney disease, renal fibrosis or acute kidney injury by the administration of an RGD mimetic integrin receptor antagonist, either as a single agent or in combination with other agents.
• Composition and Methods for Treating Chronic Kidney Disease
  申请人：MERCK SHARP & DOHME CORP

  公开号：US20190307735A1

  公开（公告）日：2019-10-10

  This invention relates to the treatment of chronic kidney disease, including diabetic nephropathy, focal segmental glomerulosclerosis (FSGS), nephrotic syndrome, non-diabetic chronic kidney disease, renal fibrosis or acute kidney injury by the administration of an RGD mimetic integrin receptor antagonist, either as a single agent or in combination with other agents.